In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
ESC Congress 2020 Register

Immunometabolism and Atherosclerosis

Commented by Assoc. Prof. Giuseppe Danilo Norata

Vascular Biology and Physiology
Vascular Diseases


 

Cellular metabolism is now recognized to impact the function of immune cells. Several immune cells subsets, upon activation, adapt their cellular metabolism to cope with proliferation and/or differentiation. These changes interest the key six cellular metabolic pathways, specifically, glycolysis, the tricarboxylic acid (TCA) cycle, the pentose phosphate pathway, fatty acid oxidation, fatty acid synthesis and amino acid metabolism. In parallel, a global cellular metabolic rewiring occurs which bring in front other metabolic pathways including those related to tryptophan and cholesterol. These processes become are even more peculiar in the context of cardiovascular diseases, where the crosstalk of systemic to cellular metabolism creates the environmental setting to reprogram immune cells in the context of acute heart failure, myocarditis, heart transplant rejection, atherosclerosis and diet induced obesity.

Aim of this position paper by the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology was to present a brief overview of the recent developments in the immunometabolism field, focusing on its role in atherosclerosis.

Metabolites are not just ‘fuels’ in their pathways but they are also effectors and signalling molecules that regulate the immune system. Moreover systemic and microenvironment-induced changes in basic metabolic pathways can skew the balance between pro- and anti-inflammatory responses in atherosclerosis, this paves the way for identyfing key immunometabolic reactions governing plaque development and stability that will give a new understanding of disease processes, and likely lead to novel therapeutic approaches to prevent and treat atherosclerotic CVDs. The position papers also highlights the potential impact of immunometabolic markers and targets in clinical cardiovascular medicine.

This manuscript is part of a spotlight issue of Cardiovascular Research which discusses several aspects connecting immunometabolism in the field of atherosclerosis and cardiovascular diseases.

References


  • Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology.  Daniel F J Ketelhuth et al. Cardiovascular Research, Volume 115, Issue 9, July 2019, Pages 1385–1392.
  • Immunometabolic function of cholesterol in cardiovascular disease and beyond. Laurent Yvan-Charvet; Fabrizia Bonacina; Rodolphe Renè Guinamard; Giuseppe Danilo Norata. Cardiovascular Research, Volume 115, Issue 9, July 2019, Pages 1393–1407.
  • The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: immune homeostatic mechanisms in the artery wall. Daniel FJ Ketelhuth. Cardiovascular Research, Volume 115, Issue 9, July 2019, Pages 1408–1415.
  • Immunometabolism orchestrates training of innate immunity in atherosclerosis. Julia van Tuijl, Leo A B Joosten; Mihai G Netea; Siroon Bekkering; Niels P Riksen. Cardiovascular Research, Volume 115, Issue 9, July 2019, Pages 1416–1424.
  • Mechanotransduction, immunoregulation, and metabolic functions of CD31 in cardiovascular pathophysiology. Giuseppina Caligiuri. Cardiovascular Research, Volume 115, Issue 9, July 2019, Pages 1425–1434.
  • The effect of diet on hypertensive pathology: is there a link via gut microbiota-driven immunometabolism? Hamdi A Jama; Anna Beale; Waled A Shihata; Francine Z Marques. Cardiovascular Research, Volume 115, Issue 9, July 2019, Pages 1435–1447.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

Contact us

ESC Working Group on Aorta & Peripheral Vascular Diseases

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot

06903, Sophia Antipolis, FR

Tel: +33.4.92.94.76.00